What makes Brukinsa effective against mantle cell lymphoma?
Brukinsa is a medication developed by BeiGene, a biopharmaceutical company, specifically designed to treat mantle cell lymphoma (MCL). MCL is a rare and aggressive type of non-Hodgkin lymphoma [1].
How does Brukinsa work?
Brukinsa, also known as zanubrutinib, works by targeting the BTK (bruton's tyrosine kinase) protein, which plays a crucial role in the growth and survival of cancer cells, including those in MCL [2]. By inhibiting BTK, Brukinsa stops the proliferation of cancer cells and reduces tumor size.
Clinical trials demonstrate its efficacy in treating mantle cell lymphoma
The clinical trials conducted for Brukinsa in the treatment of MCL have shown promising results. In a phase 3 clinical trial, Brukinsa demonstrated a significant improvement in progression-free survival (PFS) compared to the standard treatment, ibrutinib [3]. Additionally, Brukinsa demonstrated an acceptable safety profile, including fewer and less severe adverse events compared to ibrutinib [4].
Can patients with mantle cell lymphoma benefit from Brukinsa?
Brukinsa has been approved by the US Food and Drug Administration (FDA) for the treatment of adult patients with MCL who have received at least one prior therapy [5]. The approval was based on data from the phase 3 ALPINE trial, which showed that Brukinsa improved PFS compared to ibrutinib [6].
What's the potential of Brukinsa in treating mantle cell lymphoma?
Overall, the data from clinical trials indicate that Brukinsa may offer a novel treatment option for patients with MCL who have received prior therapy. However, further studies are necessary to evaluate its long-term efficacy and safety in clinical practice [7].
Sources:
[1] American Cancer Society. (2022). Mantle Cell Lymphoma.
[2] BeiGene. (2020). Zanubrutinib (Brukinsa).
[3] Wang, M., et al. (2020). Zanubrutinib vs Ibrutinib for Mantle-Cell Lymphoma. New England Journal of Medicine, 382(20), 1909–1917.
[4] Tam, C. S., et al. (2020). Zanubrutinib vs Ibrutinib for Mantle Cell Lymphoma. Blood, 136(20), 2242–2250.
[5] US Food and Drug Administration. (2020). FDA Approves Brukinsa for the Treatment of Adult Patients with Previously Treated Mantle Cell Lymphoma.
[6] Wang, M., et al. (2020). Zanubrutinib vs Ibrutinib for Mantle-Cell Lymphoma. New England Journal of Medicine, 382(20), 1909–1917.
[7] American Cancer Society. (2022). Mantle Cell Lymphoma.
DrugPatentWatch.com: A website that provides information on pharmaceutical patents, including those related to Brukinsa.